McCune-Albright Syndrome: A Comprehensive Review of Pathophysiology, Clinical Manifestations, and Therapeutic Approaches
Main Article Content
Abstract
McCune-Albright Syndrome (MAS) is a rare and complex disorder that primarily affects the bones, skin, and endocrine system. It is characterized by a mosaic pattern of somatic mutations in the GNAS gene, leading to constitutive activation of adenylate cyclase and excessive production of cyclic AMP (cAMP). This dysregulated cAMP signaling pathway results in a wide spectrum of clinical manifestations, including polyostotic fibrous dysplasia, café-au-lait skin pigmentation, and various endocrinopathies such as precocious puberty, hyperthyroidism, and hypercortisolism. This comprehensive review aims to provide an in-depth understanding of the pathophysiological mechanisms underlying MAS, a detailed exploration of the diverse clinical features, and a discussion of the current and emerging therapeutic strategies for managing this rare disorder. The article synthesizes research findings, clinical experiences, and genetic insights to shed light on the challenges faced by healthcare providers in diagnosing and treating patients with MAS.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008 May 19;3:12.
II. Turan S, Bastepe M. GNAS Spectrum of Disorders. Curr Osteoporos Rep. 2015 Jun;13(3):146-58.
III. Leet AI, Collins MT. Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. J Child Orthop. 2007 Mar;1(1):3-17.
IV. Belsuzarri TA, Araujo JF, Melro CA, Neves MW, Navarro JN, Brito LG, Pontelli LO, de Abreu Mattos LG, Gonçales TF, Zeviani WM. McCune-Albright syndrome with craniofacial dysplasia: Clinical review and surgical management. Surg Neurol Int. 2016;7(Suppl 6):S165-9.
V. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res. 2004 Apr;19(4):571-7.
VI. Bercaw-Pratt JL, Moorjani TP, Santos XM, Karaviti L, Dietrich JE. Diagnosis and management of precocious puberty in atypical presentations of McCune-Albright syndrome: a case series review. J Pediatr Adolesc Gynecol. 2012 Feb;25(1):e9-e13.
VII. Shetty S, Varghese RT, Shanthly N, Paul TV. Toxic Thyroid Adenoma in McCune-Albright Syndrome. J Clin Diagn Res. 2014 Feb;8(2):281-2.
VIII. Chakraborty D, Mittal BR, Kashyap R, Manohar K, Bhattacharya A, Bhansali A. Radioiodine treatment in McCune-Albright syndrome with hyperthyroidism. Indian J Endocrinol Metab. 2012 Jul;16(4):654-6.
IX. Chen M, Eugster EA. Central Precocious Puberty: Update on Diagnosis and Treatment. Paediatr Drugs. 2015 Aug;17(4):273-81.
X. Estrada A, Boyce AM, Brillante BA, Guthrie LC, Gafni RI, Collins MT. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome. Eur J Endocrinol. 2016 Nov;175(5):477-483.
XI. G Buff Passone C, Kuperman H, Cabral de Menezes-Filho H, Spassapan Oliveira Esteves L, Lana Obata Giroto R, Damiani D. Tamoxifen Improves Final Height Prediction in Girls with McCune-Albright Syndrome: A Long Follow-Up. Horm Res Paediatr. 2015;84(3):184-9.
XII. Benhamou J, Gensburger D, Messiaen C, Chapurlat R. Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study. J Bone Miner Res. 2016 Dec;31(12):2167-2172.